Cancer is a controllable disease with advanced medical approaches and stakeholder collaborative efforts. Despite significant financial investments in cancer research, progress remains limited, particularly in sub-Saharan Africa (SSA), where most cancer types remain understudied. This review provides a comprehensive analysis of current trends in cancer education, awareness, and screening uptake in SSA. It also identifies prospects for advancing cancer education and sustaining research efforts in the region. We included 86 studies in this review, synthesizing evidence from systematic reviews and meta-analyses to present an unbiased overview of SSA-specific trends. A structured table was derived from 52 studies, comprising 26 on cervical cancer, 10 on breast cancer, and 16 on other cancer types. The review highlights positive outcomes from awareness campaigns of the included designs. However, low participant retention in trials and underdeveloped research infrastructure in SSA have hindered the translation of awareness into clinical trial participation and vaccine uptake. While the review identifies promising preventive, predictive, and personalized approaches for cancer awareness in SSA, it calls for more rigorous study designs with robust data analysis to address potential biases. Furthermore, sustained financial and cultural support is critical to align future research with SSA’s healthcare priorities and societal perceptions.
Antimicrobial resistance (AMR) is commonly framed as a consequence of mutation and selection, yet this perspective does not fully explain the speed and scale of global resistance dissemination. Here, we argue that AMR is better understood as an amplification problem, in which horizontal gene transfer particularly conjugation governs the spread of resistance genes across bacterial populations and ecological compartments. Conjugative plasmids couple high transfer efficiency with broad host range, enabling rapid dissemination of resistance determinants, including those conferring resistance to last-resort antibiotics. This review synthesizes evidence showing that conjugation is shaped by tightly constrained trade-offs between transfer efficiency, fitness cost, plasmid copy number, and ecological context. These constraints render conjugation a rate-limiting step in dissemination dynamics, such that even modest reductions in transfer efficiency can substantially reduce plasmid persistence and spread. At the same time, plasmids exhibit adaptive features, including compensatory evolution and dynamic regulation of replication, that stabilize their persistence and complicate intervention. This duality positions conjugation as both a central driver of AMR and a tractable therapeutic target. We review emerging strategies to disrupt conjugation, including small-molecule inhibitors, CRISPR-based systems, phage approaches, and ecological interventions, and highlight key challenges related to delivery, evolutionary escape, and real-world implementation. We propose that targeting gene flow rather than gene emergence alone offers a complementary strategy for controlling AMR. By reframing conjugation as a controllable bottleneck in resistance amplification, future interventions may shift the trajectory of AMR from expansion toward containment.
Background: Parkinson’s disease (PD) is a complex neurodegenerative disorder requiring multidimensional treatment approaches. Recent breakthroughs in precision medicine and growing evidence for music therapy efficacy present new opportunities for comprehensive PD management that addresses both biological mechanisms and quality of life outcomes Objectives: This mini review evaluates the current state of precision medicine and music therapy interventions for PD, with three primary aims: (1) to synthesize evidence for genetic-based treatments and music-based interventions, (2) to identify potential synergies between these approaches, and (3) to highlight critical implementation challenges in clinical practice. Finding: Our analysis revealed that precision medicine approaches, including GBA1-targeted venglustat and LRRK2 kinase inhibitors, show significant promise in clinical trials when guided by genetic profiling. Concurrently, music therapy demonstrates robust clinical benefits, with RAS producing 15–20% improvements in gait parameters and group singing programs enhancing both speech function and psychosocial wellbeing. Emerging technologies, particularly wearable sensors and adaptive AI platforms, are enhancing the precision and personalization of both treatment modalities. However, we identified persistent challenges including the need for standardized biomarkers in precision medicine and more rigorous clinical validation for music therapy protocols. Conclusions: The strategic integration of precision medicine and music therapy offers a novel, patient-centered framework for PD management that simultaneously targets pathological mechanisms and functional outcomes. Future implementation should focus on overcoming accessibility barriers, conducting large-scale longitudinal studies, and developing integrated treatment protocols that combine genetic insights with personalized neuromodulation approaches.